5-Amino-1MQ — Safety, Research, Risks & Legal Status

Not medical advice. 5-Amino-1MQ is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	5A1MQ, NAD booster precursor
Category	Peptide
NAD	Nicotinamide adenine dinucleotide; coenzyme in metabolism and energy production
CCF1	NAD-consuming enzyme; breaks down NAD+; target of 5-Amino-1MQ inhibition
sirtuins	NAD+-dependent proteins; involved in aging, stress response, and metabolism
US legal status	Research chemical; not FDA-approved; sold as research only; direct NAD+ boosters (NMN, NR) are dietary supplements but not proven as anti-aging

What is 5-Amino-1MQ?

Synthetic organic molecule studied to inhibit NAD-consuming enzyme Nic(K)NAD transferase (CCF1) and raise NAD+ levels; framed as NAD+ metabolism enhancer to support cellular energy. Unlike direct NAD+ precursors (NMN, NR), 5-Amino-1MQ blocks breakdown of NAD+ rather than supplying precursors.

How it works

5-Amino-1MQ inhibits Nic(K)NAD transferase (CCF1/TiqA), an enzyme that breaks down NAD+. By reducing NAD+ catabolism, the molecule increases intracellular NAD+ concentration and NAD+/NADH ratio, potentially enhancing sirtuin, PARP, and other NAD+-dependent enzyme activity.

Background & history

5-Amino-1MQ was identified as a potent CCF1 inhibitor in preclinical screening around 2020. Initial publication showed NAD+ elevation and metabolic benefits in mouse models. The compound generated interest in biohacking and anti-aging communities despite complete absence of human data; commercial availability followed quickly.

What the research says

Preclinical studies in mice show metabolic and lifespan effects; minimal to no human data; marketed anti-aging and muscle benefit claims are speculative and based on animal work. Mouse studies reported increased NAD+ levels, improved glucose tolerance, and modest lifespan extension, but translation to humans is unvalidated.

Reported effects

Reported to increase NAD+ in animal muscle tissue
Studied to improve glucose metabolism in mouse models
Animal work suggests potential mitochondrial support
May influence sirtuin pathways in preclinical research
Preclinical data suggest possible metabolic rate elevation and fat loss

Dosing & administration (informational)

Animal studies used doses of 50-150 mg/kg body weight intraperitoneally or orally, resulting in significant NAD+ elevation. No human trials have been conducted. Oral absorption is minimal, making injection the typical route in research markets. Bioavailability, metabolism, and human-equivalent dosing are entirely unknown.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Human safety data absent; preclinical only
Oral bioavailability is poor; often sold as injection to bypass absorption
Injection-route compounds carry infection and quality risk if not GMP sterile
No toxicity data in humans; animal data shows no major red flags but is limited
Long-term effects unknown; pregnancy/nursing avoid
Off-target effects unknown; NAD+ is ubiquitous and affects many pathways

Drug & supplement interactions

NAD+-dependent pathways are broad; off-target effects on sirtuins, PARPs, and CD38 possible
Potential interaction with other NAD+ precursors (NMN, NR); redundancy and safety untested
Diabetes medications: NAD+ elevation may affect glucose control; risk unquantified
Alcohol consumption: ethanol uses NAD+; interaction direction and magnitude unknown

Who should avoid it

Diabetes or metabolic disorders (NAD+ elevation could disrupt glucose homeostasis)
Pregnancy and nursing (no safety data; developmental risk unknown)
Active cancer or history of cancer (NAD+ elevation may affect tumor metabolism unpredictably)
Liver or kidney disease (metabolism unclear; clearance at risk)
Combined use with prescription NAD+-modulating drugs without medical supervision

How it is commonly combined

5-Amino-1MQ is sometimes combined with other NAD+ precursors (NMN, NR) or mitochondrial agents (CoQ10, SS-31) in informal biohacking protocols, but no studies validate safety, synergy, or efficacy of any combination in humans.

Legal & regulatory. Research chemical; not FDA-approved; sold as research only; direct NAD+ boosters (NMN, NR) are dietary supplements but not proven as anti-aging

Quality & harm reduction

T
h
i
r
d
-
p
a
r
t
y
C
O
A
w
i
t
h
p
u
r
i
t
y
a
n
d
i
d
e
n
t
i
t
y
c
o
n
f
i
r
m
a
t
i
o
n
.
I
f
i
n
j
e
c
t
e
d
:
H
P
L
C
9
8
%
+
p
u
r
i
t
y
,
e
n
d
o
t
o
x
i
n
t
e
s
t
(
l
e
s
s
t
h
a
n
0
.
2
5
I
U
/
k
g
)
,
s
t
e
r
i
l
e
s
i
n
g
l
e
-
u
s
e
v
i
a
l
s
.
I
f
o
r
a
l
:
e
n
s
u
r
e
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
(
G
M
P
)
s
u
p
p
l
i
e
r
;
c
h
e
c
k
f
o
r
f
i
l
l
e
r
s
a
n
d
c
o
n
t
a
m
i
n
a
n
t
s
.
C
o
l
d
s
t
o
r
a
g
e
r
e
q
u
i
r
e
d
(
2
-
8
°
C
o
r
-
2
0
°
C
f
r
e
e
z
e
)
;
d
o
n
o
t
r
e
u
s
e
o
p
e
n
e
d
v
i
a
l
s
.

Safer, legal alternative we recommend

Regular resistance training and adequate protein intake. Exercise and protein directly stimulate muscle protein synthesis via proven pathways; no injection risk and proven long-term safety.

See our recommended pick

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Does 5-Amino-1MQ boost NAD+ in humans?

Unknown. Mouse studies show NAD+ increases; human data does not exist. Marketing claims exceed evidence.

Is it better than NMN or NR?

Different approach (CCF1 inhibition vs. direct supplement), but human data for ANY of them as anti-aging is weak. NMN/NR have slightly more human research.

Will it help me build muscle?

Mouse data is suggestive but far from proof. No human trials in gym-goers or athletes.

What if I take too much?

Unknown. No human dosing studies; overdose risks uncharacterized.

Is oral form effective?

Likely poor absorption; injection used in research. Oral pills marketed online are unvalidated for bioavailability.

References & further reading

NAD+ metabolism and aging: Nature Aging and Aging reviews
CCF1 inhibition and NAD+ elevation: preclinical biochemistry journals
Sirtuin pathways and health: Trends in Endocrinology and Metabolism
5-Amino-1MQ preclinical studies: limited published literature; mainly in Chinese-language journals or preprints
NAD+ boosters and human longevity: ongoing debate in gerontology with minimal long-term RCT data